Long-term Immune Protection in COVID-19 Patients

Overview

Acronym
LIPiC
Investigators
  • Dr. Ishac Nazy

    McMaster University

Contacts
  • Rumi Clare

    McMaster University

General Design

Study design
Cohort
Start Year
2020
General Information on Follow Up (profile, frequency)
For the COVID-19 positive and negative cohorts, paticipant's antibodies are tested approximately 14 days after the onset of symptoms (baseline), 6 months and 1 year later. For the COVID-19 vaccinated cohort, antibody testing will be conducted up to 5 times: baseline (pre-vaccination), 3 weeks after first vacinnation, 3 weeks after second vaccination, 6 months and 12 months post-vaccination.
Recruitment Target
  • Individuals
Number of Participants
600
Number of Participants with Biological Samples
600
Supplementary information about number of participants

COVID-19 positive cohort planned to be conducted on approximately 200 patients

COVID-19 negative cohort planned to be conducted on approximately 200 patients

COVID-19 vaccinated cohort planned to be conducted on approximately 200 non-infected participants

Access

Availability of data and biosamples

Possible Access to Data
Possible Access to Biosamples
Other

Timeline

Populations

LIPiC - Positive Cohort

Selection Criteria

Countries
  • Canada
Territory
Hamilton, Ontario
Health Status
  • Recovered from COVID-19 infection
Other Criteria
Tested as positive from the reverse transcriptase polymerase chain reaction (RT-PCR) test

Sources of Recruitment

Specific Population
  • Clinic patients
Supplementary Information
Study participants were recruited from patients who recovered from COVID-19 infection and were initially identified by treating physicians, Public Health and through hospital discharge databases that include hospitals in Hamilton, Ontario, Canada (Hamilton General Hospital, Juravinski Hospital, McMaster University Medical Centre, and St. Joseph’s Healthcare).

Sample Size

Number of Participants
200
Number of Participants with Biological Samples
200

Data Collection Events

# Name Description Start End
0 LIPiC - Positive Cohort - Baseline 2020 (September) Ongoing
1 LIPiC - Positive Cohort - Follow-up 1 2021 (March) Ongoing
2 LIPiC - Positive Cohort - Follow-up 2 2021 (September) Ongoing
LIPiC - Negative Cohort

Selection Criteria

Countries
  • Canada
Territory
Hamilton, Ontario
Health Status
  • Recovered from COVID-19 infection
Other Criteria
Tested as negative from the reverse transcriptase polymerase chain reaction (RT-PCR) test

Sources of Recruitment

Specific Population
  • Clinic patients
Supplementary Information
Study participants were recruited from patients who recovered from COVID-19 infection and were initially identified by treating physicians, Public Health and through hospital discharge databases that include hospitals in Hamilton, Ontario, Canada (Hamilton General Hospital, Juravinski Hospital, McMaster University Medical Centre, and St. Joseph’s Healthcare).

Sample Size

Number of Participants
200
Number of Participants with Biological Samples
200

Data Collection Events

# Name Description Start End
0 LIPiC - Negative Cohort - Baseline 2020 (September) Ongoing
1 LIPiC - Negative Cohort - Follow-up 1 2021 (March) Ongoing
2 LIPiC - Negative Cohort - Follow-up 2 2021 (September) Ongoing
LIPiC - Vaccinated Cohort

Selection Criteria

Countries
  • Canada
Territory
Hamilton, Ontario
Health Status
  • Non-infected with COVID-19
Other Criteria
Planning to be vaccinated with vaccines against SARS-CoV-2

Sources of Recruitment

General Population
  • Selected sample

Sample Size

Number of Participants
200
Number of Participants with Biological Samples
200

Individual Studies Included

Acronym Name Study design Participants Countries

Harmonization Projects Included

Acronym Name

Networks

Acronym Name Studies

Datasets

Name Type Data Collection Events Variables
Last Update: 2021-07-30 14:36